Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ESRRG | P62508 | 2/20 | 0.32 |
| ▸ | ESRRB | O95718 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2401867 | 1.00 | NOTUM (0.38) | NOTUMCACNA1HMAPTSMN1; SMN2ESRRG | |
| SCHEMBL2397806 | 1.00 | NOTUM (0.38) | NOTUMCACNA1HMAPTSMN1; SMN2ESRRG | |
| SCHEMBL2401807 | 0.90 | MEN1 (0.35) | NOTUMMAPTSMN1; SMN2POLBTP53 | |
| SCHEMBL2398360 | 0.90 | NOTUM (0.45) | NOTUMMAPTSMN1; SMN2POLB | |
| SCHEMBL2400290 | 0.90 | NOTUM (0.45) | NOTUMMAPTSMN1; SMN2POLB | |
| SCHEMBL2396008 | 0.88 | LPAR1 (0.38) | NOTUMMAPTSMN1; SMN2POLBTP53 | |
| SCHEMBL2216720 | 0.88 | LPAR1 (0.38) | NOTUMMAPTSMN1; SMN2POLBTP53 | |
| SCHEMBL2401845 | 0.87 | NOTUM (0.36) | NOTUMMAPTESRRGESRRBCYP19A1 | |
| SCHEMBL2400496 | 0.86 | HSP90AA1 (0.39) | NOTUMESRRGESRRBCYP19A1NR1H4 | |
| SCHEMBL2214597 | 0.85 | NR1H4 (0.39) | NOTUMMAPTSMN1; SMN2POLBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | claimed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2011-09-29 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | NOTUM 3691/4885CACNA1H 3126/4885MAPT 4877/4885 |
| US-20110237528-A1 | COMPOSITIONS AND METHODS COMPRISING IMIDAZOLE AND TRIAZOLE DERIVATIVES | CFTR, PKD1, PKD2 | NOTUM 3951/4885CACNA1H 2885/4885MAPT 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.